Classification
- Anatomical main groupJAnti-infectives for systemic use
- Therapeutic subgroupJ05
- Pharmacological subgroupJ05A
- Chemical subgroupJ05AJ
- Chemical substanceJ05AJ03Dolutegravir
Where it is registered
Each register and historical list with its number of registrations and a few of them.
At a glance
- ATC code
- J05AJ03
- ATC group
- Anti-infectives for systemic use
- Registers
- 10
- Historical lists
- 2
- Registrations
- 96
- With their own page
- 64
- Companies
- 29
All medicines with Dolutegravir
Human medicines from every register that match Dolutegravir by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
97 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Dolutegravir | United States | 10MG, 5MG | film | Marketed | Laurus Generics INC |
| dolutegravir sódico | Brazil | Authorised | Fundação Oswaldo Cruz | ||
| dolutegravir sódico | Brazil | Authorised | Blanver Farmoquimica e Farmaceutica S.A. | ||
| dolutegravir sódico | Brazil | Authorised | Laboratorio Farmaceutico do Estado de Pernambuco Governador Miguel Arraes S/A - Lafepe | ||
| dolutegravir sódico | Brazil | Authorised | Cristália Produtos Químicos Farmacêuticos Ltda. | ||
| Dolutegravir Teva 50 mg, filmomhulde tabletten | Netherlands | Filmomhulde tablet | Authorised | Teva GmbH | |
| PMS-Dolutegravir | Canada | 50 MG | Tablet | Marketed | Pharmascience INC |
| Dolutegravir Teva 50 mg filmom obložene tablete | Croatia | Filmom obložena tableta | Not marketed | TEVA GmbH | |
| Sandoz Dolutegravir | Canada | 50 MG | Tablet | Authorised | Sandoz Canada Incorporated |
| lamivudina + dolutegravir sódicoCombination | Brazil | Authorised | Blanver Farmoquimica e Farmaceutica S.A. | ||
| lamivudina + dolutegravir sódicoCombination | Brazil | Authorised | Fundação Oswaldo Cruz | ||
| DovatoCombination | United States | 50MG BASE; 300MG | tablet | Marketed | Viiv Hlthcare |
| JulucaCombination | United States | 50MG BASE; 25MG BASE | tablet | Marketed | Viiv Hlthcare |
| Tivicay | United States | 10MG BASE, 25MG BASE, 50MG BASE | tablet | Marketed | Viiv Hlthcare |
| Tivicay PD | United States | 5MG BASE | tablet, for suspension | Marketed | Viiv Hlthcare |
| DovatoCombination | European Union | Authorised | ViiV Healthcare B.V. | ||
| TriumeqCombination | United States | 600MG BASE; 50MG BASE; 300MG | tablet | Marketed | Viiv Hlthcare |
| Triumeq PDCombination | United States | 60MG BASE; 5MG BASE; 30MG | tablet, for suspension | Marketed | Viiv Hlthcare |
| Dovato 50 MG/300 MG Comprimidos Recubiertos con PeliculaCombination | Spain | 52.6 mg + 300 mg | comprimido recubierto con película | Marketed | Viiv Healthcare B.V. |
| Tivicay 5 MG Comprimidos Dispersables | Spain | 5,26 mg | comprimido dispersable | Marketed | Viiv Healthcare B.V. |
| Triumeq 5 MG/60 MG/30 MG Comprimidos DispersablesCombination | Spain | 5,26 mg + 30 mg + 70,20 mg | comprimido dispersable | Marketed | Viiv Healthcare B.V. |
| DovatoCombination | Canada | 50 MG + 300 MG | Tablet | Marketed | Viiv Healthcare Ulc |
| JulucaCombination | European Union | Authorised | ViiV Healthcare B.V. | ||
| Juluca 50 MG/25 MG Comprimidos Recubiertos con PeliculaCombination | Spain | 52,62 mg + 27,50 mg | comprimido recubierto con película | Marketed | Viiv Healthcare B.V. |
| Tivicay | European Union | Authorised | ViiV Healthcare BV |